Cargando…

Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors

Human immunodeficiency virus (HIV) therapy has evolved over the last 20 years from mono-drug therapy given five times daily to regimens consisting of three or four drugs combined in a single-tablet dosed once daily. To allow once-daily administration, several drugs require pharmacokinetic boosting b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nathan, Bavithra, Bayley, Jake, Waters, Laura, Post, Frank A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108106/ https://www.ncbi.nlm.nih.gov/pubmed/25134475 http://dx.doi.org/10.1007/s40121-013-0013-7

Ejemplares similares

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy
por: von Hentig, Nils
Publicado: (2015)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat
por: Hohmann, Nicolas, et al.
Publicado: (2020)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis
por: Valin, Nadia, et al.
Publicado: (2016)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
por: Squillace, Nicola, et al.
Publicado: (2018)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

1568 Use of the Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in a Predominantly African-American HIV Infected Population
por: Bryant, Paul, et al.
Publicado: (2014)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley, Rustin D, et al.
Publicado: (2016)

Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method
por: Midde, Narasimha M., et al.
Publicado: (2016)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
por: Hutapea, Hotma Martogi Lorensi, et al.
Publicado: (2018)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2020)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
por: Koneru, Pratibha C, et al.
Publicado: (2019)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Patterns of resistance development with integrase inhibitors in HIV
por: Mbisa, Jean L, et al.
Publicado: (2011)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Update on Adverse Effects of HIV Integrase Inhibitors
por: Kolakowska, Agnieszka, et al.
Publicado: (2019)

Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2020)

Identification and Optimization of a Novel HIV-1 Integrase Inhibitor
por: Adu-Ampratwum, Daniel, et al.
Publicado: (2022)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
por: Meixenberger, Karolin, et al.
Publicado: (2014)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants
por: Smith, Steven J., et al.
Publicado: (2021)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase
por: Gupta, Kushol, et al.
Publicado: (2016)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
por: Foster, Emma G., et al.
Publicado: (2022)

Novel 3′-Processing Integrase Activity Assay by Real-Time PCR for Screening and Identification of HIV-1 Integrase Inhibitors
por: Sakkhachornphop, Supachai, et al.
Publicado: (2015)

Integrase and integration: biochemical activities of HIV-1 integrase
por: Delelis, Olivier, et al.
Publicado: (2008)

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo dynamics of integrase inhibitor resistance mutations
por: Nguyen, Nga, et al.
Publicado: (2013)

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors
por: Meixenberger, Karolin, et al.
Publicado: (2017)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq
por: Dudley, Dawn M, et al.
Publicado: (2014)

Resistance to Integrase Inhibitors
por: Métifiot, Mathieu, et al.
Publicado: (2010)

Investigation of anti-HIV activity, cytotoxicity and HIV integrase inhibitory activity of polyherbal formulation BH extracts
por: Balraj, S, et al.
Publicado: (2014)

Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. Integrase inhibition
por: Lee-Huang, Sylvia, et al.
Publicado: (2007)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_79ud8605t5h8pkd39pjpv4r6li